SOFIE is Awarded $5M from Three Major SBIR Grants
SOFIE’s GNEXT PET/CT Continues to Unlock Applications in Preclinical Imaging
Today SOFIE announces that the National Institutes of Health (NIH) has awarded the company three grants totaling $5M under the Small Business Innovation Research (SBIR) program.
Upcoming Webinar: 18F-FDG PET/CT: Its Role in Clinical Cancer Care
SOFIE is the WMIC 2017 Commercial Innovation of the Year Award Winner for the innovative GNEXT PET/CT.
Article: Aetna Agrees with SNMMI, Updates Coverage Policy
In this session, Dr. Czernin will present an overview of the role of 18F-FDG PET/CT in the management of cancer patient care, focusing on its role as diagnostic, prognostic, intermediate endpoint and predictive biomarker, and more.
Interview: Business Opportunities in the New Age of Medicine
Just this month Aetna expanded their coverage, now including gallium-68 (Ga-68) dotatate PET, upgrading its prior "experimental" status to now “medically necessary.”
Upcoming Webinar: Utility of PET/CT for Melanoma
SOFIE co-founders Philipp Czernin and Melissa Moore speak with Reach Further about the beginnings of the company, carving out their own niche in the medical world, China, and more.
In this session, Dr. Bridwell will detail the key aspects of the disease, including incidence, risk factors, and more.